FZata, Inc. is developing a ground-breaking “Live Biologics In A Pill” platform for oral delivery of live biologics. Live Biologics In A Pill will open up a new route of oral administration for innovative live biologic therapeutics. FZata is pleased to announce that our lead drug, FZ002, has advanced to manufacturing stage and IND-enabling studies.

Dr. Zhiyong Yang, PhD, President and CEO FZata, commented, “We are very excited to be leading this groundbreaking work. Our first-in-class live LBP drug candidate will be manufactured for clinical trials by a world-class CDMO that is experienced with LBPs.